Patient Management in Neurology Intensive Care During COVID-19 Pandemic Period
Objective: This study aims to evaluate data from coronavirus disease-2019 (COVID-19) patients with neurological manifestations hospitalized in the intensive care unit (ICU). Materials and Methods: The study included data from COVID-19 patients with neurological manifestations hospitalized in ICU. P...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Yayinevi
2022-06-01
|
| Series: | Türk Nöroloji Dergisi |
| Subjects: | |
| Online Access: | https://tjn.org.tr/jvi.aspx?pdir=tjn&plng=eng&un=TJN-43420&look4= |
| _version_ | 1797919880896315392 |
|---|---|
| author | Fergane Memmedova Semra Arı Sevingil Fatma Altuntaş Kaya Fatma Ger Akarsu Zaur Mehdiyev Ulviyyat Jafarova Özlem Aykaç Atilla Özcan Özdemir |
| author_facet | Fergane Memmedova Semra Arı Sevingil Fatma Altuntaş Kaya Fatma Ger Akarsu Zaur Mehdiyev Ulviyyat Jafarova Özlem Aykaç Atilla Özcan Özdemir |
| author_sort | Fergane Memmedova |
| collection | DOAJ |
| description | Objective: This study aims to evaluate data from coronavirus disease-2019 (COVID-19) patients with neurological manifestations hospitalized in the intensive care unit (ICU).
Materials and Methods: The study included data from COVID-19 patients with neurological manifestations hospitalized in ICU. Patients’ demographic characteristics, risk factors, laboratory results, treatment methods, mechanical ventilation methods, use of non-invasive techniques to meet O2 requirements, clinical outcome at discharge and after three months, and mortality rates were evaluated.
Results: The study included 25 patients. Mean age of the patients was 66.76±12.93. Fifty two percent of the patients were male. Of the patients 96% had a positive polymerase chain reaction test, and 92% had lung involvement. The comorbidities of the patients were hypertension (48%), diabetes mellitus (28%), coronary artery disease (28%), cerebrovascular disease (20%), cancer (20%), and chronic obstructive pulmonary disease (12%). Seventy two percent of the patients presented with stroke. Of the patients %12 presented with encephalopathy, whereas patients with epilepsy and myasthenia gravis accounted for 8%. Patients’ average length of stay in ICU was 13.16±12.44 days. Pressure-synchronized intermittent mandatory ventilation mode was used in 56% of patients. Number of intubation days was 9.5±12.26. All patients were treated with favipiravir and antiaggregant, 92% with steroids and antibacterial therapy, 52% with antiaggregant, 20% with plasma therapy, 8% with cytokine filter and immunoglobulin therapy, and 4% with monoclonal antibody therapy. During hospitalization, mortality rate was 48%, good clinical outcome rate was 36%.
Conclusion: The rates of poor clinical outcomes are seen to be high during in-hospital treatment and follow-up of COVID-19 patients presenting with neurological symptoms, as well as at discharge. |
| first_indexed | 2024-04-10T13:52:20Z |
| format | Article |
| id | doaj.art-a31beeef33e5442db06312f31ddfbd8c |
| institution | Directory Open Access Journal |
| issn | 1309-2545 |
| language | English |
| last_indexed | 2024-04-10T13:52:20Z |
| publishDate | 2022-06-01 |
| publisher | Galenos Yayinevi |
| record_format | Article |
| series | Türk Nöroloji Dergisi |
| spelling | doaj.art-a31beeef33e5442db06312f31ddfbd8c2023-02-15T16:10:38ZengGalenos YayineviTürk Nöroloji Dergisi1309-25452022-06-01282788310.4274/tnd.2022.43420Patient Management in Neurology Intensive Care During COVID-19 Pandemic PeriodFergane Memmedova0https://orcid.org/0000-0003-3021-1688Semra Arı Sevingil1https://orcid.org/0000-0002-6766-1095Fatma Altuntaş Kaya2https://orcid.org/0000-0001-9497-7709Fatma Ger Akarsu3https://orcid.org/0000-0003-3171-4535Zaur Mehdiyev4https://orcid.org/0000-0002-0917-0036Ulviyyat Jafarova5https://orcid.org/0000-0002-2572-6954Özlem Aykaç6https://orcid.org/0000-0003-4987-0050Atilla Özcan Özdemir7https://orcid.org/0000-0003-4028-1751Eskisehir Osmangazi University Faculty of Medicine, Department of Neurology, Eskisehir, TurkeyEskisehir Osmangazi University Faculty of Medicine, Department of Neurology, Eskisehir, TurkeyEskisehir Osmangazi University Faculty of Medicine, Department of Neurology, Eskisehir, TurkeyEskisehir Osmangazi University Faculty of Medicine, Department of Neurology, Eskisehir, TurkeyEskisehir Osmangazi University Faculty of Medicine, Department of Neurology, Eskisehir, TurkeyEskisehir Osmangazi University Faculty of Medicine, Department of Neurology, Eskisehir, TurkeyEskisehir Osmangazi University Faculty of Medicine, Department of Neurology, Eskisehir, TurkeyEskisehir Osmangazi University Faculty of Medicine, Department of Neurology, Eskisehir, TurkeyObjective: This study aims to evaluate data from coronavirus disease-2019 (COVID-19) patients with neurological manifestations hospitalized in the intensive care unit (ICU). Materials and Methods: The study included data from COVID-19 patients with neurological manifestations hospitalized in ICU. Patients’ demographic characteristics, risk factors, laboratory results, treatment methods, mechanical ventilation methods, use of non-invasive techniques to meet O2 requirements, clinical outcome at discharge and after three months, and mortality rates were evaluated. Results: The study included 25 patients. Mean age of the patients was 66.76±12.93. Fifty two percent of the patients were male. Of the patients 96% had a positive polymerase chain reaction test, and 92% had lung involvement. The comorbidities of the patients were hypertension (48%), diabetes mellitus (28%), coronary artery disease (28%), cerebrovascular disease (20%), cancer (20%), and chronic obstructive pulmonary disease (12%). Seventy two percent of the patients presented with stroke. Of the patients %12 presented with encephalopathy, whereas patients with epilepsy and myasthenia gravis accounted for 8%. Patients’ average length of stay in ICU was 13.16±12.44 days. Pressure-synchronized intermittent mandatory ventilation mode was used in 56% of patients. Number of intubation days was 9.5±12.26. All patients were treated with favipiravir and antiaggregant, 92% with steroids and antibacterial therapy, 52% with antiaggregant, 20% with plasma therapy, 8% with cytokine filter and immunoglobulin therapy, and 4% with monoclonal antibody therapy. During hospitalization, mortality rate was 48%, good clinical outcome rate was 36%. Conclusion: The rates of poor clinical outcomes are seen to be high during in-hospital treatment and follow-up of COVID-19 patients presenting with neurological symptoms, as well as at discharge.https://tjn.org.tr/jvi.aspx?pdir=tjn&plng=eng&un=TJN-43420&look4=covid-19neurointensive carestrokeseizureencephalopathymyasthenia gravis |
| spellingShingle | Fergane Memmedova Semra Arı Sevingil Fatma Altuntaş Kaya Fatma Ger Akarsu Zaur Mehdiyev Ulviyyat Jafarova Özlem Aykaç Atilla Özcan Özdemir Patient Management in Neurology Intensive Care During COVID-19 Pandemic Period Türk Nöroloji Dergisi covid-19 neurointensive care stroke seizure encephalopathy myasthenia gravis |
| title | Patient Management in Neurology Intensive Care During COVID-19 Pandemic Period |
| title_full | Patient Management in Neurology Intensive Care During COVID-19 Pandemic Period |
| title_fullStr | Patient Management in Neurology Intensive Care During COVID-19 Pandemic Period |
| title_full_unstemmed | Patient Management in Neurology Intensive Care During COVID-19 Pandemic Period |
| title_short | Patient Management in Neurology Intensive Care During COVID-19 Pandemic Period |
| title_sort | patient management in neurology intensive care during covid 19 pandemic period |
| topic | covid-19 neurointensive care stroke seizure encephalopathy myasthenia gravis |
| url | https://tjn.org.tr/jvi.aspx?pdir=tjn&plng=eng&un=TJN-43420&look4= |
| work_keys_str_mv | AT ferganememmedova patientmanagementinneurologyintensivecareduringcovid19pandemicperiod AT semraarısevingil patientmanagementinneurologyintensivecareduringcovid19pandemicperiod AT fatmaaltuntaskaya patientmanagementinneurologyintensivecareduringcovid19pandemicperiod AT fatmagerakarsu patientmanagementinneurologyintensivecareduringcovid19pandemicperiod AT zaurmehdiyev patientmanagementinneurologyintensivecareduringcovid19pandemicperiod AT ulviyyatjafarova patientmanagementinneurologyintensivecareduringcovid19pandemicperiod AT ozlemaykac patientmanagementinneurologyintensivecareduringcovid19pandemicperiod AT atillaozcanozdemir patientmanagementinneurologyintensivecareduringcovid19pandemicperiod |